EXEL
NASDAQ · Biotechnology
Exelixis Inc
$51.35
-0.56 (-1.08%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+11.05%
1Y
+18.40%
YTD
+17.83%
Open$52.00
Previous Close$51.91
Day High$52.95
Day Low$50.80
52W High$53.93
52W Low$33.76
Volume—
Avg Volume2.46M
Market Cap13.05B
P/E Ratio15.66
EPS$3.02
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$43.59
Above
SMA 200
$41.49
Above
RSI (14)
62
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Buy
26 analysts
Price Target
+126.1% upside
Current
$51.35
$51.35
Target
$116.10
$116.10
$78.53
$116.10 avg
$123.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.07B | 1.83B | 2.68B |
| Net Income | 697.86M | 556.16M | -77,688,294 |
| Profit Margin | 33.7% | 32.0% | -2.9% |
| EBITDA | 803.71M | 676.10M | -84,355,918 |
| Free Cash Flow | — | — | -70,301,392 |
| Rev Growth | +12.9% | +12.9% | +9.9% |
| Debt/Equity | — | — | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $233.69 | +1.60% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.34 | +0.76% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.84 | +0.78% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $469.49 | +0.58% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.15 | +0.92% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $287.84 | +0.50% | 64.3 | 37.13B |